Publicacions (57) Publicacions de CARLOS JAVIER ANGUITA VELASCO

2024

  1. Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients

    Transplantation and Cellular Therapy, Vol. 30, Núm. 3, pp. 306.e1-306.e12

  2. Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial

    Vox Sanguinis, Vol. 119, Núm. 1, pp. 27-33

2023

  1. Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide

    Annals of Hematology, Vol. 102, Núm. 6, pp. 1561-1567

  2. Red Blood Cell Transfusion after Postpartum Hemorrhage: Clinical Variables Associated with Lack of Postpartum Hemorrhage Etiology Identification

    Journal of Clinical Medicine, Vol. 12, Núm. 19

  3. Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy

    Frontiers in immunology, Vol. 14, pp. 1165759

2022

  1. Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapy

    Transfusion, Vol. 62, Núm. 10, pp. 2143-2147

  2. Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation

    Frontiers in immunology, Vol. 13, pp. 1002959

  3. Clinical grade production of IL-15 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide

    Transfusion, Vol. 62, Núm. 2, pp. 374-385

  4. FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 16

  5. Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility

    International Journal of Hematology, Vol. 115, Núm. 1, pp. 61-68

2021

  1. Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide

    Frontiers in Immunology, Vol. 12

  2. Complete RH and Kell matching related to low alloimmunisation risk in sickle cell disease: prevalence and risk factors of alloimmunisation in a Spanish Tertiary Care National Reference Centre

    Blood transfusion = Trasfusione del sangue, Vol. 19, Núm. 4, pp. 292-299

  3. Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide

    Frontiers in Immunology, Vol. 12

  4. Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia

    Leukemia and Lymphoma, Vol. 62, Núm. 5, pp. 1178-1186

  5. International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Responses

    Vox Sanguinis, Vol. 116, Núm. 5, pp. e25-e43

  6. Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant

    Frontiers in Immunology, Vol. 12

  7. Next generation cytogenetics in myeloid hematological neoplasms: Detection of cnvs and translocations

    Cancers, Vol. 13, Núm. 12

  8. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation

    Annals of Hematology, Vol. 100, Núm. 2, pp. 541-553

2020

  1. Autologous stem cell transplantation for lymphoma in HIV+ patients: higher rate of infections compared with non-HIV lymphoma

    Bone Marrow Transplantation, Vol. 55, Núm. 9, pp. 1716-1725

  2. Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide

    Hematological Oncology, Vol. 38, Núm. 4, pp. 597-603